Current Report Filing (8-k)
November 05 2020 - 8:21AM
Edgar (US Regulatory)
MERRIMACK PHARMACEUTICALS INC false 0001274792 0001274792 2020-11-05 2020-11-05
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): November 5, 2020
Merrimack Pharmaceuticals, Inc.
(Exact Name of Registrant as Specified in its Charter)
|
|
|
|
|
Delaware
|
|
001-35409
|
|
04-3210530
|
(State or Other Jurisdiction
of Incorporation)
|
|
(Commission
File Number)
|
|
(IRS Employer
Identification No.)
|
One Broadway, 14th Floor
Cambridge, MA 02142
(Address of Principal Executive Offices)
Registrant’s telephone number, including area code: (617) 441-1000
(Former Name or Former Address, if Changed Since Last Report)
Securities registered under Section 12(b) of the Exchange Act:
|
|
|
|
|
Title of Class
|
|
Trading
Symbol
|
|
Name of Exchange
on Which Registered
|
Common stock, $0.01 par value per share
|
|
MACK
|
|
The Nasdaq Stock Market LLC (NASDAQ Global Market)
|
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
|
☐
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
☐
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
☐
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
☐
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR 230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR 240.12b-2).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
ITEM 7.01
|
REGULATION FD DISCLOSURE
|
On November 5, 2020, Merrimack Pharmaceuticals, Inc. (the “Company”) issued a press release announcing its financial results for the third quarter of 2020, as well as certain updates on programs underlying potential milestone payments to the Company. The full text of the press release is attached to this Current Report on Form 8-K as Exhibit 99.1. The press release was also simultaneously filed on the Company’s website. The information in this Item 7.01 of this Current Report on Form 8-K and Exhibit 99.1 shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, or incorporated by reference in any filing under the Securities Act of 1933 or the Securities Exchange Act of 1934, except as shall be expressly set forth by specific reference in such filing.
ITEM 9.01
|
FINANCIAL STATEMENTS AND EXHIBITS.
|
(d) Exhibits. The Exhibit Index set forth below is incorporated herein by reference.
EXHIBIT INDEX
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
|
|
|
|
|
|
|
|
|
|
MERRIMACK PHARMACEUTICALS, INC.
|
|
|
|
|
Date: November 5, 2020
|
|
|
|
By:
|
|
/s/ Gary L. Crocker
|
|
|
|
|
|
|
Gary L. Crocker
|
|
|
|
|
|
|
President
|
Merrimack Pharmaceuticals (NASDAQ:MACK)
Historical Stock Chart
From Aug 2024 to Sep 2024
Merrimack Pharmaceuticals (NASDAQ:MACK)
Historical Stock Chart
From Sep 2023 to Sep 2024